CompletedNCT05258123
Ginkgo Biloba Extract in the Treatment of Schizophrenia
This study assessed thinking abilities.
Medication studyAges 18–60China
Understand this study
What did researchers investigate?
This study assessed thinking abilities.
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- Beijing, ChinaSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: May 15, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Beijing HuiLongGuan Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT05258123
- Official title
Show the full official title
The Effects of Ginkgo Biloba Extract in the Treatment of Schizophrenia
Recruitment & locations
CompletedBeijing
Questions about this study
What did researchers investigate?
This study assessed thinking abilities.
Who is behind this study?
The study sponsor is Beijing HuiLongGuan Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Ginkgo Biloba Extract and Placebo oral tablet.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolarity